Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04035434 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
A Phase 1 study, sponsored by CRISPR Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT04035434 is a Phase 1 study that was terminated before completion, run by CRISPR Therapeutics. The registered enrollment target is 93 participants.
The verdict
NCT04035434, a Phase 1 study, was terminated before completion, sponsored by CRISPR Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
Interventions
- BIOLOGICAL CTX110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04035434
The ClinicalTrials.gov registry entry for NCT04035434 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CRISPR Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTX110 is the first listed.
NCT04035434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04035434 about?
NCT04035434 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)". This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
What is the current status of trial NCT04035434?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2019-07-22. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT04035434?
The interventions under investigation include: CTX110 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04035434?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.